Table 2.
Clinical-pathologic characteristics of validation cohort from TCGA
| Patients (n=314) | |||
|---|---|---|---|
| n (%) | n (%) | ||
| Gender | Age at diagnosis (Years) | ||
| Male | 209 (67) | <60 | 133(42.4) |
| Female | 105 (33) | ≥60 | 180(57.3) |
| Anatomic Subsite | Invasion peri(neural) | ||
| Tongue | 131 (42) | Yes | 134(42.7) |
| Oral cavity | 73 (23) | No | 113(36) |
| Floor of the mouth | 63(20) | NA | 63(20.1) |
| Buccal Mucosa | 22(7) | Margins | |
| Alveolar Ridge | 18 (6) | R0 | 229(72.9) |
| Hard Palate | 7 (2) | R1 | 37(11.8) |
| Tobacco | Close | 34(10.8) | |
| Yes | 215 (68.5) | NA | 14(4.5) |
| No | 90 (28.6) | HPV | |
| NA | 9 (2.9) | Positive | 32 (10.2) |
| Alcohol | Negative | 281 (89.5) | |
| Yes | 203 (64,6) | NA | 1 (0.3) |
| No | 104 (33,1) | Country | |
| NA | 7 (2,3) | United States | 212 (67) |
| TNM stage | Canada | 37(11.8) | |
| I | 12 (3.8) | Brazil | 10(3.2) |
| II | 76 (24.2) | Poland | 9(2.9) |
| III | 63 (20) | Other | 9(2.9) |
| IV | 155 (49.4) | NA | 37(11.8) |
| NA | 8 (2.5) | Vital status | |
| Treatment | Relapses/Metastasis in follow-up | 189(60.2) | |
| QT | 82(26.1) | ||
| Immunotherapy | 2(0.6) | ||
| Targeted Molecular Therapy | 1(0.3) | ||
| NA | 229(72.9) | ||
NA- Not Available; RT - Radiotherapy; QT - Chemotherapy